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S U M M A R Y
Objectives: Clostridium difﬁcile infection (CDI) is the leading cause of infectious diarrhea in North America
and Europe. The risk of CDI increases signiﬁcantly in the case where antimicrobial treatment reduces the
number of competing bacteria in the gut, thus leading to the increased availability of nutrients and loss of
colonization resistance. The objective of this study was to determine comprehensive nutritional
utilization and the chemical sensitivity proﬁle of historic and newer C. difﬁcile isolates and to examine
the possible role of the phenotype diversity in C. difﬁcile virulence.
Methods: Phenotype microarrays (PMs) were used to elucidate the complete nutritional and chemical
sensitivity proﬁle of six C. difﬁcile isolates.
Results: Of the 760 nutrient sources tested, 285 compounds were utilized by at least one strain. Among
the C. difﬁcile isolates compared, R20291, a recent hypervirulent outbreak-associated strain, appears to
have an expanded nutrient utilization proﬁle when compared to all other strains.
Conclusions: The expanded nutritional utilization proﬁle of some newer C. difﬁcile strains could be one of
the reasons for infections in patients who are not exposed to the hospital environment or not undergoing
antibiotic treatment. This nutritional proﬁle could be used to design tube feeding formulas that reduce
the risk of CDI.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Clostridium difﬁcile is a spore-forming Gram-positive pathogen
and is the leading cause of infectious diarrhea. Originally named
Bacillus difﬁcilis in the 1930s due to the difﬁculty in culturing it in the
laboratory, it is continuing to be a difﬁcult pathogen even today.1,2
The pathogenicity of C. difﬁcile depends on the action of at least one
of the two major exotoxins produced by the bacterium, named toxin
A and toxin B.3–6 Some strains also produce a binary toxin, which
belongs to the family of binary ADP-ribosylating toxins.7,8 Toxins A
and B are encoded by tcdA and tcdB, which are located in a 19.6-kb
region called the pathogenicity locus.6 The complications arising
from Clostridium difﬁcile infection (CDI) can range from mild self-
limiting diarrhea to the fatal pseudomembranous colitis.9,10 The* Corresponding author. Tel.: +1 607 253 2675; fax: +1 607 253 3943.
E-mail address: yc42@cornell.edu (Y.-F. Chang).
http://dx.doi.org/10.1016/j.ijid.2014.06.018
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).primary risk factors of CDI include antibiotic treatment, advanced
age, severe underlying illness, prior hospitalization, tube feeding,
gastrointestinal surgery, and the use of proton-pump inhibitors.11,12
However, the epidemiology of CDI has been changing in recent years.
Once considered a hospital-associated infection affecting older
people, CDI has now spread to younger populations. For example,
children are increasingly recognized as being at risk of CDI, even
without previous exposure to antibiotics or the healthcare setting.13
It is also spreading to the general community.14,15
An increase in the rate of CDI in North America and Europe is
partly explained by the emergence of hypervirulent strains
belonging to pulsed-ﬁeld type 1 and PCR ribotype 027 (NAP1/
027).16 Genome sequencing of C. difﬁcile strains has provided many
insights into the increased severity of CDI and expansion of the
host range. Comparative genomic analysis of these recent
hypervirulent strains against historic C. difﬁcile strains has shown
that several recent isolates have acquired new virulence determi-
nants and therefore can produce more fulminant CDI.17–19ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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difﬁcile hypervirulence, the nutritional and chemical phenome of C.
difﬁcile strains has not been studied. The ability to utilize different
nutrient sources coupled with the ability to survive the action of
antibiotics, chemicals, and osmotic changes, constitute the global
phenome of a bacterium. With the development of phenotype
microarrays (PMs), the high-throughput determination of bacterial
nutritional and chemical phenotype (phenome) is now possible.20–
24 Determination of the global phenome of C. difﬁcile strains is also
important, since the severity of CDI is intricately connected to
nutrient availability.25
The human gut is home to more than 100 trillion microbes.26 In
terms of available nutrition, ‘‘tight economic times are the norm’’
for these microbes.27 Therefore, a bacterium’s survival in the gut
depends on its ability to successfully compete for a seat at this
crowded table and partake of the available nutrients. The risk of
CDI increases signiﬁcantly when antimicrobial treatment reduces
the number of competing bacteria in the gut, leading to an
increased availability of nutrients and loss of colonization
resistance.28,29 The importance of this nutritional competition in
the gut is highlighted by the fact that transplantation of fecal
microﬂora from healthy individuals can cure recurrent CDI.30
Therefore, knowledge of the complete nutritional utilization and
chemical sensitivity proﬁle of pathogens such as C. difﬁcile will lead
to a better understanding of the conditions under which they are
likely to colonize and produce infection.
In this study, we deduced the complete nutritional and
chemical sensitivity proﬁle of six C. difﬁcile strains of varying
virulence. Our results revealed that some of the recent outbreak
strains have expanded metabolic potential. This expanded
nutritional usage might explain the spread of community-
associated CDI. Further, the metabolic phenotype results we
report here could help in the design of better interventions to treat
CDI patients such as those receiving tube feeding.
2. Materials and methods
2.1. Phenotype microarray experiments
The metabolic and chemical sensitivity proﬁle of C. difﬁcile
strains was measured using Biolog Phenotype MicroArrays (PM).
This PM technology consists of 20 PM panels. PMs 1–8 are linked to
nutrient utilization (metabolism) and PMs 9–20 measure the
chemical sensitivities. We analyzed the complete phenotypic
proﬁle of six divergent C. difﬁcile strains employing all 20 PMs.
Characteristics of the strains used are given in Table 1.
All experiments were conducted in a Bactron IV anaerobic
chamber (Shel Lab, OR, USA). Prior to PM experiments, all strains
were grown in anaerobic brain heart infusion (BHI) broth. PM
experiments were performed following standard Biolog Inc.
protocols.22 Brieﬂy, 300 ml of the bacteria grown in BHI broth
was plated on Biolog Universal blood agar plates and was
incubated overnight at 37 8C. A 40% transmittance cell suspensionTable 1










272563 C. difﬁcile 630 013 1982 Switzerland
645462 C. difﬁcile CD196 027 1985 France
367459 C. difﬁcile QCD-32g58 027 2004 Canada
691161 C. difﬁcile 6534 Unnamed 2006 USA
499174 C. difﬁcile QCD-23m63 078 2007 Canada
645463 C. difﬁcile R20291 027 2006 UK
NCBI, National Center for Biotechnology Information.in Biolog solution IF-0a was then prepared by re-suspending the
bacteria grown on Biolog Universal blood agar plates. This
suspension was then diluted with Biolog mix B at a ratio of
1:16. One hundred microliters of the ﬁnal cell suspension was then
transferred to each well of respective PM plates. The plates were
incubated at 37 8C for 48 h. Bacterial growth was then read at
750 nm using an ELISA reader. Each experiment was performed
with biological triplicates.
2.2. Statistical analysis
For statistical analysis of the PM data, the means of the
replicates were taken. For normalizing the data between strains,
the mean of each PM well was divided by the mean of the
respective negative plate controls. The value of each well was then
compared to the negative control value of the respective plate
using analysis of variance (ANOVA). A PM well was considered
positive if its value was 40% higher than the negative control at the
5.0% signiﬁcance level. The Model SEED database31 was then used
to predict the genome scale metabolic phenotype of C. difﬁcile. We
compared the predicted metabolic phenotype of C. difﬁcile and the
positive PM results. This comparison showed that at a 40% growth
increase cut-off from the negative control, false-positives are
completely avoided. For the chemical sensitivity panels (PM 9–20),
a 100% increase from the lowest value of each PM was considered
positive.
3. Results
3.1. Nutrient utilization proﬁle of C. difﬁcile strains
Biolog PM metabolic panels (PMs 1–8) consist of about 200
assays of carbon source metabolism, 400 assays of nitrogen
source metabolism, 100 assays of phosphorus and sulfur source
metabolism, and 100 assays of biosynthetic pathways.22 There-
fore, PMs enable the most comprehensive metabolic proﬁling of
microbial cells.22 Using PMs, we compared six C. difﬁcile strains
with varying virulence (Table 1). Multiple strains were included
in the comparison because genomic comparisons in the past have
revealed that genome variation among C. difﬁcile strains is
massive and it can have a profound effect on the strains’
virulence properties.17,18 The nutrient utilization proﬁle of the
strains tested correlates well with this observed genome
diversity.
Of the 760 nutrient sources tested, 285 compounds were
utilized by at least one strain (Figure 1). Simple sugars were
utilized well by all strains. Several complex carbohydrates such as
pectin and arbutin could also support growth similar to the levels
of simple sugars. However, there were clear differences in the
utilization of complex carbon (PM 1–2), nitrogen (PM 3), organic
phosphorus (PM 4), sulfur (PM 4), nutritional supplements (PM 5),
and peptide nitrogen sources (PM 6–8) (Supplementary Material,
Supplementary ﬁle S1). Depending upon the type of nutrient in the
medium, the amount of toxins produced by C. difﬁcile varied
several fold.24 Since the ability to use a nutrient by the bacterium
depends on its ability to be transported into the cell, we searched
TransportDB32 for C. difﬁcile genes associated with nutrient
transport. Based on TransportDB annotation, the C. difﬁcile genome
has 198 genes associated with simple sugars, complex carbohy-
drates, amino acids, and peptides (Supplementary Material,
Supplementary ﬁle S2). Many of the nutrients had more than
one gene associated with their transport, making a one-to-one
assignment of nutrient and corresponding gene association
difﬁcult. However, almost all of the nutrients that had a
transport-associated gene assigned were positive in our phenotype
microarray measurements.
Figure 1. Nutritional phenotypes of Clostridium difﬁcile strains. The complete nutritional phenotype of six C. difﬁcile strains was determined using Biolog Phenotype
MicroArray panels 1–8. Compounds that were positive in at least one strain are shown. The numbering scheme given at the top of the columns represents the strains as
follows: 1 = CD 630; 2 = CD 196; 3 = CD 6534; 4 = CD 23m63; 5 = CD 32g58; 6 = CD R20291. Each row represents a nutritional phenotype tested. The afﬁnity of nutrient
utilization is represented by a color range, as given in the scale bar at the top of the ﬁgure.
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outbreak-associated strain from the UK, appears to have an
expanded metabolic potential when compared to all other strains.
For example, this strain was found to have the highest utilization
rate of multiple compounds from PMs 1–8. In particular, strain
R20291 revealed a greater ability to utilize tetrathionate,
taurocholate, taurine, and a large number of peptides as a
nutritional source. There was no correlation between the strain
type (PCR ribotype or pulsed-ﬁeld type) and the metabolic
utilization proﬁle.
3.2. Chemical sensitivity proﬁle of C. difﬁcile strains
The Biolog PM chemical sensitivity panels (PMs 9–20) contain
100 assays of ion effects and osmolarity, 100 assays of pH effects
and pH control with deaminases and decarboxylases, and 1000
assays of chemical sensitivity.22 Each chemical sensitivity assay
includes four increasing doses of the test chemical. We considered
a strain resistant or insensitive to a chemical when there was an at
least 100% increase in growth in at least two out of these four doses
(Supplementary Material, Supplementary ﬁle S3). These assays
therefore test whether a strain is sensitive or insensitive to a
chemical and do not give information such as minimum inhibitory
concentration. As shown in Figure 2 and the Supplementary
Material (Supplementary ﬁle S3), the chemical sensitivity proﬁle
of strains also showed diversity among strains compared.
4. Discussion
All bacteria require a source of carbon, nitrogen, phosphorus,
sulfur, potassium, magnesium, calcium, iron, and vitamins for
growth. For bacteria living in the human gut, these nutrients can be
derived from diet, host mucosal secretions, or other resident (or
dietary) microbes.27 Knowing the full metabolic requirements of a
bacterium can lead to a better understanding of the conditions
under which it is likely to proliferate and enable the design of
interventions to prevent proliferation of the pathogen. Identifying
the global phenome of more than one strain is important in the
case of C. difﬁcile, as it is a species known for large-scale genome
variation. Previous studies have identiﬁed that the core genome of
C. difﬁcile is approximately 20% of the pangenome.18,33 Our PM
results presented in Figure 1 are the most comprehensive test for C.
difﬁcile nutritional requirements.
PM technology normally reports cellular phenotypes colori-
metrically using a tetrazolium redox dye to measure cell
respiration. However measuring tetrazolium dye reduction is
not feasible for C. difﬁcile, as it is a strict anaerobe. Therefore, in our
assays, we measured cell growth instead of dye reduction. This in
fact makes our readings more meaningful in terms of nutrient
utilization, as we measured actual cell multiplication by measuring
the increase in culture turbidity.
Some of the nutritional requirements of C. difﬁcile and those
nutrients responsible for the production of C. difﬁcile toxin are well
known. For example, the presence of glucose or other rapidly
metabolizable carbon sources in the bacterial growth medium
strongly represses C. difﬁcile toxin synthesis independently of
strain origin.24,34 Therefore, our ﬁnding that all strains readily
utilized simple sugars such as maltotriose, maltose, a-D-glucose, D-
fructose, and D-mannose is in agreement with these previous
ﬁndings.
The most surprising ﬁnding in our results was that strain
R20291 had an expanded nutritional utilization proﬁle when
compared to all of the other strains (Figure 1). C. difﬁcile R20291 is a
hypervirulent ribotype 027 strain, isolated from a recent outbreak
in Stoke Mandeville, UK.17 As our results indicate, this strain has a
higher capacity to utilize almost all of the nutrient sources. Thiswas found to be particularly pronounced in the case of peptide
nitrogen sources. When a strain achieves such increased capacity
to utilize a wide spectrum of nutrient sources, it is more likely to
colonize a host and this might explain why this strain has been
involved in severe CDI and outbreaks. Genome analysis of C. difﬁcile
strains that are historic (isolated before 1990s) and recent
outbreak strains have shown that new outbreak-associated strains
in the last 20 years have acquired several new genetic determi-
nants that confer increased motility and adherence in the gut,
increased resistance to bile salts, and better transmissibility
manifested through sporulation.17,18 Therefore, the increased
metabolic potential of R20291 could be the result of such gene
acquisition.
Although it might appear trivial, the ability to use some
nutrients such as taurocholic acid could have a profound effect on a
strain’s dissemination and colonization. Taurocholic acid is a bile
acid and C. difﬁcile strains have varying degrees of ability to use
taurocholate as a spore germinant.35 The expanded metabolic
potential of this strain coupled with the ability to use compounds
such as taurocholate might also explain the expansion of
community-associated CDI. Although this suggestion is specula-
tive, it is reasonable to believe that a C. difﬁcile strain that can
germinate more efﬁciently by responding to taurocholic acid in
bile and utilize a wider number of nutrients could even colonize a
host who is not exposed to antibiotics or the hospital environment.
This expanded metabolic potential is not correlated with the
strain typing scheme, as other ribotype 027 strains (Table 1) did
not have such a propensity. Rather it reﬂects the massive genome
diversity among strain types and should not be taken as a general
property of ribotype 027 strains. Our results, which showed that all
strains compared grew well within the mild acid to alkaline range,
also correlate well with those of previous studies showing that
patients receiving proton pump inhibitors (PPIs) are at increased
risk of CDI. Vegetative cells of C. difﬁcile survive better in the gut
when the pH of the gut ﬂuids is elevated following the
administration of PPIs.36
Overall, the chemicals presented in Figure 2 should be avoided
in any interventions designed to control C. difﬁcile, as these do not
affect at least some of the C. difﬁcile strains. However, the effects of
pH and pH control by deamination have a profound effect on C.
difﬁcile growth. As shown in Figure 2, acid pH is inhibitory to C.
difﬁcile. Further, different strains have varying amino acid
deamination abilities (PM10-E2-G10). Members of the genus
Clostridium have the ability to use deamination as a process to use
amino acids as the source of carbon. Therefore, the observed
differences in growth in these conditions could have adaptive
value for C. difﬁcile strains in the gut.
Current clinical practice guidelines for CDI in adults advocate
better hygiene in hospitals and among healthcare workers and the
restricted use of antibiotics based on local C. difﬁcile epidemiology,
and do not recommend the use of probiotics as it is felt that
sufﬁcient evidence to support the efﬁcacy of probiotics is lacking.37
However, the options for the treatment of elderly CDI patients and
recurrent cases are limited. The diminished ability of elderly
patients to mount a protective immune response coupled with loss
of gut microbial diversity is a recipe for CDI.38 The nutritional
afﬁnity of C. difﬁcile strains presented here offers a new avenue for
designing better interventions for ameliorating recurrent CDI
cases.
Since our results provide the most comprehensive assessment
of nutritional afﬁnity of C. difﬁcile, adjustments to the diet can be
made to reduce the amount of such nutrients reaching the gut,
thereby reducing C. difﬁcile colonization and proliferation. Such
dietary interventions designed to discourage the gut invasion of
pathogens have undergone clinical trials recently.39,40 The
increased levels of short-chain fatty acid production by distal
Figure 2. Chemical and pH sensitivity of Clostridium difﬁcile strains. The chemical and pH sensitivity proﬁle of C. difﬁcile strains was determined using Biolog Phenotype
MicroArray panels 9–14. The numbering scheme given at the top of the columns represents the strains as follows: 1 = CD 630; 2 = CD 196; 3 = CD 6534; 4 = CD 23m63; 5 = CD
32g58; and 6 = CD R20291. Each row represents a chemical tested. The scale bar at the top of the ﬁgure denotes the degree of sensitivity. The complete chemical sensitivity
data of phenotype microarray panels 9–20 are given in the Supplementary Material (supplementary ﬁle S3).
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been proposed to result in an intestinal environment unfavorable
to Shigella.27,39,40 The idea of C. difﬁcile growth control by
nutritional alteration is not new and was demonstrated in animal
models in the 1980s.28,41 Therefore, our results showing thatC. difﬁcile strains have a high propensity to use easily metabolizable
sugars and peptides are in agreement with these previous studies.
Our results also offer an avenue for reducing CDI in patients
requiring enteral tube feeding. In recent years, there has been a
substantial increase in the number of endoscopically placed
J. Scaria et al. / International Journal of Infectious Diseases 27 (2014) 20–25 25tubes for long-term enteral feeding of patients.42 Tube feeding
has been recognized as a risk factor for CDI, as the formulation
acts as a rich culture medium for C. difﬁcile growth.43,44 The
nutritional proﬁle of C. difﬁcile strains elucidated in this study
will therefore aid in drawing up an ‘exclude list’ for such tube
feeding formulations.
In summary, our results present the most comprehensive
analysis of nutritional requirements and chemical sensitivities of C.
difﬁcile strains. These deﬁnitions could be used for designing better
interventions for the treatment of recurrent CDI and also for
formulating tube feeding formulas that could reduce the CDI risk.
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